Therapies Archives - Oncology Central Oncology Central

A study @ICR_London and @royalmarsdenNHS has demonstrated that olaparib could be used to target specific mutations in #prostatecancer patients. https://t.co/Ck9b53Pqit

View all

Jobs

Connecting talent with opportunity. View our featured jobs

View all

Immuno-oncology infographic

ESMO 2019 day 3 highlights: BFAST and ClarIDHy trial findings

CAR-T cell therapy: new hope for mesothelioma patients

Panel discussion: the future of oncology

Treatment sequencing in oncology: an interview with Orazio Caffo

Optimizing outcomes and treatment sequences in EGFR mutation-positive NSCLC: recent updates

Fast-acting skin patch shows potential in developing melanoma vaccine

Addressing unmet needs in pancreatic cancer with Pascal Hammel

Lung Cancer Ambition Alliance with Giorgio Scagliotti

Combination therapy shows promise for drug-resistant acute lymphoblastic leukemia in mice

PARP inhibitors: study uncovers novel mechanism of action

Addressing unmet needs in pancreatic cancer with Pascal Hammel

Could the common cold virus treat bladder cancer?

E.coli programmed to colonize tumors in mice and deliver immunotherapy

ASCO 2019: what should you look out for?

Novel drug could be world’s first treatment for a pediatric brain cancer

ESMO Breast Cancer 2019: should HER2-positive breast cancer treatment de-escalation be personalized?

ESMO Breast Cancer 2019: good outcomes in young women with aggressive breast cancer

Pembrolizumab for small-cell lung cancer: an interview with Hyun Cheol Chung

Hematological malignancy stem cell transplants: improving matches to reduce mortality

AACR19: umbralisib trial results give support for use as a marginal zone lymphoma drug

AACR19: HER2 targeted CAR-T cell therapy shows promise in advanced sarcomas patients

AACR19: mesothelin targeted CAR-T cell therapy – a possible treatment for solid tumors

Defining aggressive or early progressing non-oncogene-addicted non-small-cell lung cancer: a separate disease entity?

Login

Therapies

Must read

Immuno-oncology infographic

ESMO 2019 day 3 highlights: BFAST and ClarIDHy trial findings

CAR-T cell therapy: new hope for mesothelioma patients

Panel discussion: the future of oncology

Treatment sequencing in oncology: an interview with Orazio Caffo

Optimizing outcomes and treatment sequences in EGFR mutation-positive NSCLC: recent updates

Fast-acting skin patch shows potential in developing melanoma vaccine

Must watch

Addressing unmet needs in pancreatic cancer with Pascal Hammel

Emerging treatment options for pancreatic cancer with Thomas Seufferlein

Lung Cancer Ambition Alliance with Giorgio Scagliotti

Combination therapy shows promise for drug-resistant acute lymphoblastic leukemia in mice

PARP inhibitors: study uncovers novel mechanism of action

Addressing unmet needs in pancreatic cancer with Pascal Hammel

Could the common cold virus treat bladder cancer?

E.coli programmed to colonize tumors in mice and deliver immunotherapy

ASCO 2019: what should you look out for?

Novel drug could be world’s first treatment for a pediatric brain cancer

ESMO Breast Cancer 2019: should HER2-positive breast cancer treatment de-escalation be personalized?

ESMO Breast Cancer 2019: good outcomes in young women with aggressive breast cancer

Pembrolizumab for small-cell lung cancer: an interview with Hyun Cheol Chung

Hematological malignancy stem cell transplants: improving matches to reduce mortality

AACR19: umbralisib trial results give support for use as a marginal zone lymphoma drug

AACR19: HER2 targeted CAR-T cell therapy shows promise in advanced sarcomas patients

AACR19: mesothelin targeted CAR-T cell therapy – a possible treatment for solid tumors

Defining aggressive or early progressing non-oncogene-addicted non-small-cell lung cancer: a separate disease entity?

Stay up to date

Oncology Central Newsletter